drugset / Trial / NCT00051181

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

NCT00051181

Phase 3 Completed Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.

Timeline

Start
2000-01
Primary completion
2003-06
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Latanoprost Small molecule 0.005 %
Subject Travoprost Other / unclassified 0.004 %